Related Experiment Video

Updated: Mar 11, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.0K

Dual modulation of MCL-1 and mTOR determines the response to sunitinib

Mohamed Elgendy, Amal Kamal Abdel-Aziz, Salvatore Lorenzo Renne

    The Journal of Clinical Investigation
    |November 29, 2016
    PubMed

    Insights

    Sunitinib resistance in cancer is linked to increased MCL-1 stability and mTORC1 signaling. Inhibiting these pathways enhances sunitinib efficacy, offering new therapeutic strategies for overcoming treatment resistance.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Therapeutics

    Background:

    • Sunitinib is a multi-tyrosine kinase inhibitor used in cancer treatment.
    • Many patients treated with sunitinib eventually develop resistance.
    • Understanding sunitinib's targets is crucial for overcoming resistance.

    Purpose of the Study:

    • To investigate the mechanisms of sunitinib resistance.
    • To explore the roles of MCL-1 and mTORC1 signaling in sunitinib response.
    • To identify potential therapeutic targets for enhancing sunitinib efficacy.

    Main Methods:

    • In vitro and in vivo experiments using cancer cells and tumors.
    • Analysis of MCL-1 protein stability and mTORC1 signaling.
    • Assessment of sunitinib's effects at different concentrations.
    • Evaluation of proteasomal degradation pathways.
    • Comparison of patient samples before and after sunitinib treatment.

    Main Results:

    • Clinically relevant sunitinib doses enhance MCL-1 stability and mTORC1 signaling, promoting cell survival.
    • Inhibition of MCL-1 or mTORC1 synergizes with sunitinib to reduce tumor growth.
    • Higher sunitinib doses induce cytotoxicity by decreasing MCL-1 and inhibiting mTORC1.
    • Sunitinib modulates MCL-1 stability via proteasomal degradation, influenced by ERK and GSK3β.
    • Increased MCL-1 and mTORC1 activity in patients correlates with sunitinib resistance.

    Conclusions:

    • Cancer cells develop resistance to sunitinib through enhanced MCL-1 stability and mTORC1 signaling.
    • Targeting MCL-1 or mTORC1 can sensitize cells to sunitinib and overcome resistance.
    • Differential modulation of these pathways by sunitinib dose is mechanistically significant.
    • MCL-1 and mTORC1 are potential biomarkers and therapeutic targets for sunitinib resistance.

    More Related Videos

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.8K
    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    8.8K

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.0K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.1K
    Interactions Between Signaling Pathways01:19

    Interactions Between Signaling Pathways

    Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
    Convergence and divergence, and cross-talk between signaling pathways
    Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
    7.7K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    5.4K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K